Alvotech stock may be undervalued following its $125 million public offering, with the company screening as attractively priced on several valuation measures. The share price has declined about 64% over the past five years, yet the stock trades at a price-to-sales ratio of 2.2 times, well below the biotech industry average of 12.0 times and the peer average of 6.5 times. A fair P/S ratio implied by Simply Wall St's model sits at about 5.1 times, more than double the current level, suggesting investors are paying a lower price for Alvotech's sales than might be expected. The company's biosimilar pipeline progress, including the FDA review of AVT16, and the recent capital raise support the investment case, though increased leverage and ongoing funding needs may keep the perceived risk profile elevated. The key question is whether Alvotech can convert its pipeline and capital raises into durable revenue and margin gains that prompt a rerating, or whether the current valuation discount proves to be a value trap.
AlvotechArticle suggests stock is undervalued based on low P/S ratio and analyst fair value estimate, and highlights recent $125M offering and pipeline progress as supporting investment case.